'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity

Gene Therapy

Volumn 12, Issue 20, 2005, Pages 1517-1525

  Kim, J H ^a   Chen, J ^a   Majumder, N ^a   Lin, H ^a   Falo Jr , L D ^a   You, Z ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

CD11c Bcl xl; Dendritic cells; DNA vaccine; TRP2hsp70; Tumor models

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; MEMBRANE PROTEIN; PROTEIN BCL XL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CELL INTERACTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE CONTROL; GENE TARGETING; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, NEOPLASM; AUTOANTIGENS; BCL-X PROTEIN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GENE THERAPY; GLIOMA; HSP70 HEAT-SHOCK PROTEINS; INTRAMOLECULAR OXIDOREDUCTASES; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TIME FACTORS; VACCINES, DNA;

ANIMALIA;

EID: 27144512475     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302584     Document Type: Article

References (56)

1. Editoral. Destination: Tumor eradication. Nat Immunol 2003; 4: 813.
2. Berzofsky JA et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113: 1515-1525.
3. Gurunathan S et al. DNA vaccines: Immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927-974.
4. Steinman RM et al. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002; 109: 1519-1526.
5. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227-238.
6. Stevenson FK et al. DNA fusion gene vaccines against cancer: From the laboratory to the clinic. Immunol Rev 2004; 199: 156-180.
7. Bonifaz LC et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199: 815-824.
8. Todryk S et al. Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 2003; 110: 1-9.
9. Millar DG et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 2003; 9: 1469-1476.
10. Chen CH et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 1035-1042.
11. Hauser H et al. Secretory heat-shock protein as a dendritic cell-targeting molecule: A new strategy to enhance the potency of genetic vaccines. Gene Therapy 2004; 11: 924-932.
12. Kim J et al. Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther 2005; 11: 941-949.
13. Dieu MC et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373-386.
14. Ronchese F et al. Killing of dendritic cells: A life cut short or a purposeful death? J Exp Med 2001; 194: 1723-1726.
15. + T cells. J Exp Med 1997; 185: 2133-2141.
16. + T cell by exogenous cell-associated antigens. Immunity 2002; 17: 211-220.
17. Hon H et al. bcl-xl is critical for dendritic cell survival in vivo. J Immunol 2004; 173: 4425-4432.
18. Sallusto F et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
19. Hou WS et al. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol 2004; 6: 583-589.
20. Kim TW et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003; 112: 109-117.
21. Sasaki S et al. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 2001; 19: 543-547.
22. Leitner WW et al. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 2000; 60: 51-55.
23. Chattergoon MA et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 2000; 18: 974-979.
24. Heath WR et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199: 9-26.
25. L in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood 2004; 103: 2779-2786.
26. Brocker T et al. Targeted Expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 1997; 185: 541.
27. Bloom MB et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 453-459.
28. Prins R et al. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003; 63: 8487-8491.
29. Zhu DZ et al. Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci USA 1991; 88: 9568-9572.
30. Bronte V et al. Genetic Vaccination with 'self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000; 60: 253-258.
31. Bellone M et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000; 165: 2651-2656.
32. Insug O et al. A DNA vaccine expressing TRP2 induces T cell-mediated protection against mouse glioblastoma. Cancer Gene Therapy 2003; 10: 678-688.
33. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005; 7: 3-17.
34. Kutzler MA et al. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004; 114: 1241-1244.
35. + T Cell responses induced by DNA vaccination of outbred animals. J Immunol 2002; 169: 3837-3846.
36. Leitner WW et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003; 9: 33-39.
37. Alvarez D et al. Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses. J Immunol 2005; 174: 1664-1674.
38. Torres CA et al. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 1997; 158: 4529-4532.
39. Nopora A et al. Bcl-2 controls dendritic cell longevity in vivo. J Immunol 2002; 169: 3006-3014.
40. Kim TW et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003; 171: 2970-2976.
41. + memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum Gene Ther 2005; 16: 26-34.
42. + T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003; 4: 579-585.
43. Miller MJ et al. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci USA 2004; 101: 998-1003.
44. Wang R-F et al. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 2002; 20: 149-154.
45. Bowne WB et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190: 1717-1722.
46. + T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
47. Merad M et al. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99: 1676-1682.
48. Elsas A et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J Exp Med 2001; 194: 481-490.
49. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-832.
50. Turk MJ et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200: 771-782.
51. Hugues S et al. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004; 5: 1235-1242.
52. Jelley-Gibbs DM et al. Repeated stimulation of CD4 effector T cells can limit their protective function. J Exp Med 2005; 201: 1101-1112.
53. Hunt C et al. Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotides sequence of human hsp70. Proc Natl Acad Sci USA 1985; 82: 6455-6459.
54. Cheng EH et al. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 1996; 379: 554-556.
55. Cobbold S et al. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 1984; 312: 548-551.
56. Qin S et al. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 1987; 17: 1159-1165.